Colorectal cancer (CRC) patients undergoing chemotherapy often experience anemia, oxidative stress, and immune suppression, significantly impacting their quality of life and treatment outcomes. Normobaric oxygen (NBO) therapy, which delivers oxygen at atmospheric pressure with elevated oxygen concentration, has shown a potential to enhance erythropoiesis, reduce oxidative stress, and modulate immune function. However, its efficacy in CRC patients remains underexplored. This study aims to evaluate the effects of NBO exposures on (1) supporting erythropoiesis by measuring erythropoietin (EPO) levels and hypoxia-inducible factors (HIF-1α), (2) reducing oxidative stress and improving stress and emotional well-being, and (3) modulating immune function by assessing cytokine profiles. Secondary objectives include assessing the impact of NBO on patient-reported outcome measures (PROMs) such as stress, anxiety, depression, and quality of life. This is a prospective, randomized, double-blind, placebo-controlled clinical trial. A total of 254 CRC patients undergoing chemotherapy will be randomized 1:1 to receive either active NBO therapy (n=127) or placebo NBO therapy (n=127). The intervention consists of 10 NBO sessions over five weeks. Primary outcomes include biomarkers of erythropoiesis, oxidative stress, and immune response. Secondary outcomes assess quality of life and psychological well-being. Data will be collected at baseline, mid-intervention, post-intervention, and during two follow-up visits (3- and 6-months post-intervention). The study hypothesizes that NBO therapy will improve erythropoiesis, reduce oxidative stress, and enhance immune function in CRC patients, leading to improved quality of life and clinical outcomes. Findings from this trial may establish NBO as a novel supportive therapy for CRC patients undergoing chemotherapy.
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Erythropoietin (EPO) concentration
Timeframe: From enrollment to the end of 6th month follow-up
Hypoxia-inducible factor-1α (HIF-1α)
Timeframe: From enrollment to the end of 6th month follow-up
Reticulocyte count
Timeframe: From enrollment to the end of 6th month follow-up
Red blood cell (RBC)
Timeframe: From enrollment to the end of 6th month follow-up
Hemoglobin concentration (HGB)
Timeframe: From enrollment to the end of 6th month follow-up
Hematocrit
Timeframe: From enrollment to the end of 6th month follow-up
Serum creatinine
Timeframe: From enrollment to the end of 6th month follow-up
Estimated glomerular filtration rate (eGFR)
Timeframe: From enrollment to the end of 6th month follow-up
Alanine aminotransferase (ALT)
Timeframe: From enrollment to the end of 6th month follow-up
Aspartate aminotransferase (AST)
Timeframe: From enrollment to the end of 6th month follow-up
Fasting glucose
Timeframe: From enrollment to the end of 6th month follow-up
Fasting insulin
Timeframe: From enrollment to the end of 6th month follow-up
Lipid profile
Timeframe: From enrollment to the end of 6th month follow-up
Iron metabolism (serum iron, total iron-binding capacity [TIBC]
Timeframe: From enrollment to the end of 6th month follow-up
Serum albumin
Timeframe: From enrollment to the end of 6th month follow-up
C-reactive protein (CRP)
Timeframe: From enrollment to the end of 6th month follow-up
Reactive oxygen species (ROS) level
Timeframe: From enrollment to the end of 6th month follow-up]
Serum cortisol
Timeframe: From enrollment to the end of 6th month follow-up
Gamma-aminobutyric acid (GABA)
Timeframe: From enrollment to the end of 6th month follow-up
Dopamine
Timeframe: From enrollment to the end of 6th month follow-up
Serotonin
Timeframe: From enrollment to the end of 6th month follow-up
Fibrinogen
Timeframe: From enrollment to the end of 6th month follow-up
Glycated hemoglobin (HbA₁c)
Timeframe: From enrollment to the end of 6th month follow-up
Dehydroepiandrosterone-sulfate (DHEA-S)
Timeframe: From enrollment to the end of 6th month follow-up
Systolic blood pressure (SBP)
Timeframe: From enrollment to the end of 6th month follow-up
Diastolic blood pressure (DBP)
Timeframe: From enrollment to the end of 6th month follow-up
Heart rate (HR)
Timeframe: From enrollment to the end of 6th month follow-up
Body mass index (BMI)
Timeframe: From enrollment to the end of 6th month follow-up
Body surface area (BSA)
Timeframe: From enrollment to the end of 6th month follow-up
Waist-to-hip ratio (WHR)
Timeframe: From enrollment to the end of 6th month follow-up
Tumor necrosis factor-α (TNF-α)
Timeframe: From enrollment to the end of 6th month follow-up
Interleukin-1β (IL-1β)
Timeframe: From enrollment to the end of 6th month follow-up
Interleukin-6 (IL-6)
Timeframe: From enrollment to the end of 6th month follow-up
Interleukin-10 (IL-10)
Timeframe: From enrollment to the end of 6th month follow-up
Monocyte chemoattractant protein-1 (MCP-1/CCL2)
Timeframe: From enrollment to the end of 6th month follow-up
Macrophage inflammatory protein-1α (MIP-1α/CCL3)
Timeframe: From enrollment to the end of 6th month follow-up
Macrophage inflammatory protein-1β (MIP-1β/CCL4)
Timeframe: From enrollment to the end of 6th month follow-up
Vascular endothelial growth factor A (VEGF-A)
Timeframe: From enrollment to the end of 6th month follow-up
Platelet-derived growth factor-BB (PDGF-BB)
Timeframe: From enrollment to the end of 6th month follow-up